NasdaqGS:GERNBiotechs
A Look At Geron (GERN) Valuation As Investors Weigh RYTELO Growth Against Recent Losses
Recent price performance and business context
Geron (GERN) has been moving on mixed recent returns, with a 7.7% decline over the past day and a 12.4% drop over the past week, set against gains over the past month and past 3 months.
The stock last closed at US$1.55. The company reports annual revenue of US$183.881 and a net loss of US$85.782, positioning it as a commercial stage oncology player built around its telomerase inhibitor RYTELO for myelodysplastic syndromes.
See our latest analysis...